Tigecycline treatment causes a decrease in peripheral blood platelet

被引:8
作者
Huang, Yu [1 ]
Chen, Libin [2 ]
Su, Handuo [3 ]
Huang, Zhenwei [3 ]
Li, Xiaoyi [3 ]
Huang, Shubao [3 ,4 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Thorac Surg, Fuzhou, Peoples R China
[2] Zhangpu Cty Hosp, Dept Lab Med, Zhangzhou, Peoples R China
[3] Zhangpu Cty Hosp, Dept Crit Care Med, Zhangzhou, Peoples R China
[4] Zhangpu Hosp, Dept Crit Care Med, Zhangzhou, Peoples R China
关键词
Tigecycline; risk factors; elderly; inflammation indexes; blood platelet; antibiotics; SAFETY; INFECTIONS; EFFICACY; HYPOFIBRINOGENEMIA;
D O I
10.1080/1120009X.2022.2153315
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tigecycline with broad-spectrum activity against pathogens has advantages in the treatment of severe infections in clinical. Accompany with the huge increase of tigecycline usage, more side effects began to arouse people's attention. The aim of this study was to assess the impact of tigecycline treatment on peripheral blood platelet in patients with severe infections. We retrospectively retrieved demographic and laboratory data in 24 cases of tigecycline-treated patients with severe infections. 18 patients (75%) who were administered tigecycline experienced a decrease in platelet count. The ages of platelet decrease group are significant older than normal group. In the platelet decreased group, the platelet count was significant decreased after 3 days tigecycline treatment. 9 patients' platelet count recovered in 5 days after tigecycline treatment withdraw. Platelet decrease in patient after tigecycline treatment, which can be reversed after tigecycline discontinuation. Tigecycline-induced platelet decrease is associated with age.
引用
收藏
页码:491 / 495
页数:5
相关论文
共 29 条
[1]   The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].
Babinchak, T ;
Ellis-Grosse, E ;
Dartois, N ;
Rose, GM ;
Loh, E .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367
[2]   Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature [J].
Bender, Jennifer K. ;
Cattoir, Vincent ;
Hegstad, Kristin ;
Sadowy, Ewa ;
Coque, Teresa M. ;
Westh, Henrik ;
Hammerum, Anette M. ;
Schaffer, Kirsten ;
Burns, Karen ;
Murchan, Stephen ;
Novais, Carla ;
Freitas, Ana R. ;
Peixe, Luisa ;
Del Grosso, Maria ;
Pantosti, Annalisa ;
Werner, Guido .
DRUG RESISTANCE UPDATES, 2018, 40 :25-39
[3]   The rising problem of antimicrobial resistance in the intensive care unit [J].
Brusselaers, Nele ;
Vogelaers, Dirk ;
Blot, Stijn .
ANNALS OF INTENSIVE CARE, 2011, 1
[4]   Tigecycline-induced coagulopathy: a literature review [J].
Cui, Nannan ;
Cai, Hongliu ;
Li, Zhitao ;
Lu, Yuting ;
Wang, Guobin ;
Lu, Anwei .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) :1408-1413
[5]   High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria [J].
De Pascale, Gennaro ;
Montini, Luca ;
Pennisi, Mariano Alberto ;
Bernini, Valentina ;
Maviglia, Riccardo ;
Bello, Giuseppe ;
Spanu, Teresa ;
Tumbarello, Mario ;
Antonelli, Massimo .
CRITICAL CARE, 2014, 18 (03)
[6]   A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia [J].
Duran, Fulya Yilmaz ;
Yildirim, Halil ;
Sen, Emre Mehmet .
TURKISH JOURNAL OF HEMATOLOGY, 2018, 35 (01) :83-84
[7]   The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam [J].
Ellis-Grosse, EJ ;
Babinchak, T ;
Dartois, N ;
Rose, G ;
Loh, E .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S341-S353
[8]   Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature [J].
Fan, Qiaomei ;
Huang, Wei ;
Weng, Yayun ;
Xie, Xianze ;
Shi, Zheng .
MEDICINE, 2020, 99 (43) :E22638
[9]  
Gauer RL, 2012, AM FAM PHYSICIAN, V85, P612
[10]  
Giryes S, 2017, CURR DRUG SAF, V12, P7, DOI 10.2174/1574886311666160920090714